Cypress Investors Resist $163M Ramius Takeover Bid
Cypress Bioscience Inc. shareholders have accused the company's board of directors of breaching its fiduciary duties by failing to adequately consider whether a $163 million hostile takeover bid by a unit...To view the full article, register now.
Already a subscriber? Click here to view full article